Literature DB >> 6437837

Influence of fasting on lipolytic response to adrenergic agonists and on adrenergic receptors in subcutaneous adipocytes.

J Ostman, P Arner, H Kimura, H Wahrenberg, P Engfeldt.   

Abstract

The influence of 1 week's total fasting on the lipolytic effect of adrenergic agonists and on the binding of adrenergic antagonists was examined in isolated adipocytes of subcutaneous specimens removed from the hypogastric and the femoral sites in seventeen obese women. In the femoral adipocytes the lipolytic sensitivity to isopropyl noradrenaline decreased 30-fold (P less than 0.01) during fasting. The specific binding of the radioligands (-)-[3H]-dihydroalprenolol and (-)-[125I]-cyanopindolol decreased significantly during fasting, essentially owing to a reduction in the receptor density. In adipocytes from the hypogastric region no such changes were found. For both tissue regions fasting induced a right-ward shift in the dose-response curve for the inhibitory effect of the alpha 2 agonist, clonidine, on theophylline-induced lipolysis, corresponding to a 10-fold decrease in sensitivity. There was also a significant decrease of about 20% in the alpha 2-adrenoceptor density, as estimated with the radioligand [3H]-yohimbine. The results suggest that the regulation of the lipid mobilization in man by the sympathetic nervous system during fasting occurs not only through an increase in the level of circulating noradrenaline but also through changes in the adrenergic receptor density of the adipocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437837     DOI: 10.1111/j.1365-2362.1984.tb01199.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

1.  Mechanisms underlying regional differences in lipolysis in human adipose tissue.

Authors:  H Wahrenberg; F Lönnqvist; P Arner
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

2.  Lipomobilizing effects of procaterol and yohimbine in the conscious dog: comparison of endocrinological, metabolic and cardiovascular effects.

Authors:  P Valet; M Taouis; M A Tran; P Montastruc; M Lafontan; M Berlan
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

3.  Prospective and controlled studies of the actions of insulin and catecholamine in fat cells of obese women following weight reduction.

Authors:  P Löfgren; J Hoffstedt; E Näslund; M Wirén; P Arner
Journal:  Diabetologia       Date:  2005-10-13       Impact factor: 10.122

4.  Lipolytic catecholamine resistance due to decreased beta 2-adrenoceptor expression in fat cells.

Authors:  F Lönnqvist; H Wahrenberg; L Hellström; S Reynisdottir; P Arner
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

5.  Adipocyte lipolysis in normal weight subjects with obesity among first-degree relatives.

Authors:  L Hellström; D Langin; S Reynisdottir; M Dauzats; P Arner
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

6.  Lipolysis during fasting. Decreased suppression by insulin and increased stimulation by epinephrine.

Authors:  M D Jensen; M W Haymond; J E Gerich; P E Cryer; J M Miles
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

7.  Antilipolytic effects of N6-phenylisopropyladenosine and prostaglandin E2 in fat-cells of obese volunteers before and during energy restriction.

Authors:  H Kather; E Wieland; B Fischer; G Schlierf
Journal:  Biochem J       Date:  1985-11-01       Impact factor: 3.857

8.  Demonstration of an in vivo functional beta 3-adrenoceptor in man.

Authors:  S Enocksson; M Shimizu; F Lönnqvist; J Nordenström; P Arner
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

9.  Catecholamine resistance in fat cells of women with upper-body obesity due to decreased expression of beta 2-adrenoceptors.

Authors:  S Reynisdottir; H Wahrenberg; K Carlström; S Rössner; P Arner
Journal:  Diabetologia       Date:  1994-04       Impact factor: 10.122

10.  A pathogenic role of visceral fat beta 3-adrenoceptors in obesity.

Authors:  F Lönnqvist; A Thöme; K Nilsell; J Hoffstedt; P Arner
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.